Milademetan - Rain Oncology
Alternative Names: DS 3032b; DS-3032; RAIN-32Latest Information Update: 27 Jun 2024
At a glance
- Originator Rigel Pharmaceuticals
- Developer Daiichi Sankyo Inc; National Cancer Center Hospital East; Rain Oncology; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Cyclohexanes; Halogenated hydrocarbons; Indoles; Pyrans; Pyrrolidines; Small molecules; Spiro compounds
- Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Preclinical Malignant-mesothelioma
- Discontinued Acute myeloid leukaemia; Liposarcoma; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Sarcoma
Most Recent Events
- 26 Jun 2024 Discontinued - Phase-I for Lymphoma (Late-stage disease, Second-line therapy or greater) in USA (PO) prior to June 2024 (Rain Oncology pipeline, June 2024) (Rigel Pharmaceuticals pipeline, June 2024) (Daiichi Sankyo, pipeline, June 2024)
- 26 Jun 2024 Discontinued - Phase-II for Sarcoma (Inoperable/Unresectable, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in Japan (PO) prior to June 2024 (Rain Oncology pipeline, June 2024) (Rigel Pharmaceuticals pipeline, June 2024) (Daiichi Sankyo, pipeline, June 2024)
- 25 Jun 2024 Discontinued - Phase-I for Acute myeloid leukaemia (Refractory metastatic disease, Second-line therapy or greater) in Japan (PO) prior to June 2024 (Rain Oncology pipeline, June 2024) (Rigel Pharmaceuticals pipeline, June 2024) (Daiichi Sankyo, pipeline, June 2024)